Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
Public ClinicalTrials.gov record NCT03611153. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Hemodynamic Effects of a Novel Myeloperoxidase Inhibitor With Exercise in Heart Failure With Preserved Ejection Fraction - A Randomized, Double-Blind, Placebo Controlled Proof of Principle Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
Study identification
- NCT ID
- NCT03611153
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2018
- Primary completion
- Feb 10, 2022
- Completion
- Feb 23, 2022
- Last update posted
- Jan 7, 2025
2018 – 2022
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Heart Failure trials
Other public records listing Heart Failure. Sorted by last update posted; newest first. Not a recommendation.
- NCT07794930: Integrating Values Based Communication in Heart Failure Management Not yet recruiting
- NCT05585125: A Preliminary Study for INFORMED Recruiting
- NCT07232030: Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure Recruiting
- NCT07771231: Kosmos PLAX EF Pivotal Study Active, not recruiting
- NCT06812533: Alleviant ALLAY-HFrEF Study Recruiting
- NCT05685303: Alleviant ALLAY-HF Study Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03611153, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 7, 2025 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03611153 live on ClinicalTrials.gov.